Indoco Remedies Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Indoco Remedies Ltd. authored by Prabhudas Lilladhar and published by - Trendlyne research reports.
Item: Indoco Remedies Ltd.
Rating: 3
Author: Prabhudas Lilladhar

Keep track of all breaking news and updates on Indoco Remedies Ltd. from all sources in a single place.

Load latest

Indoco Remedies Ltd.

13 Aug 2025, 09:51AM

299.05

-3.09%

Company Update

Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

We are pleased to inform the final approval of the Company''s Abbreviated New Drug Application (ANDA) for Rivaroxaban Tablets USP from USFDA.

pdf

Indoco Remedies Ltd.

09 Aug 2025

299.05

-3.09%

Company Update

Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Publication of Newspaper Advertisement pursuant to MCA Circulars of 78th AGM of the Company to be held on 11th September, 2025 through VC/OAVM.

pdf

Indoco Remedies Ltd.

08 Aug 2025

299.05

-3.09%

SAST

Indoco Remedies Ltd - 532612 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

BSE India

The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aditi M Panandikar & Others

pdf

Indoco Remedies Ltd.

04 Aug 2025

299.05

-3.09%

Company Update

Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Credit Rating

BSE India

Intimation of Revision in Credit Rating

pdf

Indoco Remedies Ltd.

01 Aug 2025

299.05

-3.09%

Company Update

Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements

BSE India

We wish to inform you that Company has entered into a Sale Agreement & Lease Agreement on 31st July,2025 for sale and lease back of part of the Company''s movable properties at its Waluj Facility.

pdf

Indoco Remedies Ltd.

30 Jul 2025

299.05

-3.09%

Company Update

Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Pursuant to Regulation 30(6) read with Para A of Part A of Schedule III of the SEBI (LODR) Regulation 2015, we wish to inform you that the senior management of the Company shall be meeting analyst/investor through virtual meet on 11-08-2025 at 10.00 am.

pdf

Indoco Remedies Ltd.

28 Jul 2025

299.05

-3.09%

Earnings Call

Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

BSE India

Enclosed Transcript of Earnings Conference Call held on 24-07-2025 in respect of Unaudited Standalone and Consolidated Financial Results for the quarter ended 30-06-2025.

pdf

Indoco Remedies Ltd.

25 Jul 2025

299.05

-3.09%

'Sell' Indoco Remedies Shares Maintains Dolat Capital Post Q1 Results, Sees 36% Downside Here's Why

NDTV Profit

Dolat Capital maintains Sell' rating on Indoco Remedies and revises target price

Indoco Remedies Ltd.'s price crossed below 50Day SMA today

Indoco Remedies Ltd.

25 Jul 2025

299.05

-3.09%

Company Update

Indoco Remedies Ltd - 532612 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper publication of Unaudited Standalone and consolidated Financial Results for the quarter ended 30-06-2025

pdf

Indoco Remedies Ltd.

25 Jul 2025

299.05

-3.09%

Indoco Remedies (INDR IN) Q1FY26 Result Update Cost...

Hold: Indoco Remedies Ltd.

Target

Prabhudas Lilladhar

Indoco Remedies' (INDR) Q1FY26 EBITDA was largely in line. Though margins and regulated sales have recovered QoQ but they are still below its historical run-rate given elevated expenses and ongoing FDA issues. The warning letter issued for both units has restricted growth, however USFDA has allowed to resume supplies from 2 out of 4 lines. The company cited other expenses to remain elevated in the near term. Our FY26/FY27E EBITDA has been cut by 811% to factor in low margins. At CMP, the stock is trading at 3.9x EV/domestic...